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INTRODUCTION 
The development of new aromatase inhibitors such as anastrozole
represents a significant step forward in the clinical management of
postmenopausal women with hormone-sensitive breast cancers.
The evidence in support of anastrozole – a non-steroidal, orally
administered aromatase inhibitor – as an effective antitumour
agent is outlined here. 
Anastrozole was one of the first agents to move immediately
from phase I studies of clinical pharmacology into clinically
evaluable phase III trials, due primarily to its proven effectiveness
in reducing plasma oestrogen, a recognized surrogate marker for
anti-aromatase activity. Large-scale trials have now shown that
anastrozole shows significant benefits over established endocrine
agents in both first- and second-line management of advanced
breast cancer. Consequently, anastrozole is an effective alternative
to tamoxifen for first-line treatment of advanced disease in post-
menopausal women and is now available for such use in a number
of different countries. Given this superior efficacy profile in the
management of advanced disease, anastrozole may also provide
advantages in early disease therapy, where long-term treatment
may be required to prevent disease recurrence. 
Since its introduction in 1973, tamoxifen has remained the
endocrine therapy of choice for early breast cancer in post-
menopausal patients (Early Breast Cancer Trialists’ Collaborative
Group, 1992, 1998) and has provided clinicians with an effective
and well tolerated treatment. However, tamoxifen has a number 
of limitations, based primarily on its partial oestrogen agonist
activity, which contribute directly to endometrial cell proliferation
and rarely endometrial cancer (Fisher et al, 1998) and breast
tumour stimulation. In contrast, aromatase inhibitors act by
suppressing conversion of androgen substrates into oestrogen (the
primary source of oestrogen in postmenopausal women), thereby
reducing the incidence of the more serious side-effects associated
with tamoxifen while maintaining efficacy for the management of
hormone-sensitive breast cancer. 
Primary prerequisites for effective alternative agents in the
adjuvant or preventative settings include equivalent or superior
efficacy and/or improved tolerability compared with tamoxifen,
together with easy and convenient administration. Tolerability
assumes a much greater importance in the adjuvant setting, where
prolonged therapy requires an agent with efficacy but minimal
side-effects. 
EARLY AROMATASE INHIBITORS 
The first-generation aromatase inhibitor, aminoglutethimide, has
been available for therapeutic use since the late 1970s. While clin-
ical studies showed that aminoglutethimide is as effective as
tamoxifen in advanced disease, its use was hampered by signi-
ficant problems relating to its toxicity, lack of selectivity and
inconvenient dosing regimen (Smith et al, 1982; Gale et al, 
1994). Subsequently, formestane – a second-generation steroidal
aromatase inhibitor – became available in the early 1990s but was
not an ideal replacement, given its requirement for intramuscular
administration every 2 weeks, and associated injection-site reac-
tions (Johnston and Metcalf, 1984). Both agents were also less
potent in terms of aromatase inhibition and oestrogen suppression
than the new-generation compounds. 
THIRD-GENERATION AROMATASE INHIBITORS 
The limitations of aminoglutethimide and formestane provided the
incentive to develop new-generation aromatase inhibitors. These
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include the non-steroidal agents anastrozole and letrozole, and the
oral steroidal aromatase inhibitor exemestane. All are currently
available for therapeutic use and are indicated as second-line treat-
ments for postmenopausal women with advanced breast cancer
who have progressed following first-line treatment with anti-
oestrogens (tamoxifen). Anastrozole and letrozole are now also
available for first-line treatment in these patients. While each one
provides greater selectivity and more potent inhibition of
aromatase compared with aminoglutethimide or formestane, clini-
cally relevant differences have been reported between them in
terms of their pharmacokinetic and pharmacodynamic profiles.
These differences will ultimately influence choice not only in the
treatment of advanced disease but also for their potential use in 
the adjuvant setting. 
While the three aromatase inhibitors are generally considered to
be similar, differences exist in their clinical pharmacology. These
differences are shown in Table 1. The profile for anastrozole is
superior to the others in terms of: 
● Effective dose 
● Time to achieve steady-state levels and maximal oestrogen
suppression (Plourde et al, 1995) 
● Elimination half-life (Yates et al, 1996) 
● Inhibition of intratumoural aromatase activity (Geisler et al,
1999). 
In terms of overall selectivity and based on the available published
data, anastrozole may be considered to be the most selective of the
third-generation aromatase inhibitors in the clinical setting. There
is no blunting of the response to adrenocorticotropin hormone
(ACTH) stimulation, even when administered at 10 times the
normal clinical dose of anastrozole over a period of 4 weeks,
suggesting that anastrozole therapy does not interfere with adrenal
steroidogenesis (Plourde et al, 1995) (Figure 1a). In contrast letro-
zole, administered at the usual clinical dose (2.5 mg/day), has been
shown to impact significantly on both basal and ACTH-stimulated
cortisol and aldosterone levels (Bajetta et al, 1999) (Figure 1b).
This observation may have significant clinical impact, particularly
if patients are under acute stress and when the drug is administered
for long periods of time. It is possible that adrenal suppression
may limit letrozole’s use in the adjuvant and preventative settings
where long-term administration is necessary. Exemestane is a
steroidal agent and as such possesses intrinsic hormonal activities,
thus behaving similarly to a weak androgen (Bajetta et al, 1997;
Jones et al, 1999; Michaud and Buzdar, 1999). The potential 
for unwanted androgenic side-effects, including weight-gain
(Kauffman et al, 2000), may limit its long-term utility in the
adjuvant and preventative settings. 
ANASTROZOLE IN ADVANCED BREAST CANCER 
Anastrozole as a second-line agent 
Anastrozole was the first aromatase inhibitor to demonstrate
significant survival benefits compared with the standard second-
line agent, megestrol acetate, in the treatment of postmenopausal
women with advanced breast cancer progressing after prior
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Figure 1 Impact of (A) anastrozole (5 and 10 mg/day) and (B) letrozole
(2.5 mg/day) on adrenal steroidogenesis: ACTH-stimulated results
((A) reproduced with kind permission of Kluwer Academic Publishers Boston
from Plourde et al, 1994; (B) reproduced with kind permission of Elsevier
Science Ltd from Bajetta et al, 1999) 
Table 1 Indirect comparison of dosage, pharmacokinetics and endocrine selectivity of the different aromatase inhibitors, anastrozole, letrozole and
exemestane 
Aromatase inhibitor 
Anastrozole Letrozole Exemestane 
Daily clinical dose (oral, mg/day) 1 2.5 25 
Time to steady-state plasma levels (days) 7 14–42 4 
Half-life 40–50 hours 2–4 days 24 hours 
Time to maximal oestradiol suppression (days) 3–4 2–3 by day 7* 
Intratumoural activity Yes Yes Yes 
Androgen-like structure and properties No No Yes 
Effect on sex hormone binding globulin levels None or decrease† (P = 0.003) Increase (P = 0.0001) Decrease 
Effect on basal cortisol None None or decrease (P < 0.003) None 
Effect on basal aldosterone None None or increase (P = 0.025) None 
Effect on ACTH-stimulated cortisol None Decrease (P = 0.015) ND 
Effect on ACTH-stimulated aldosterone None Decrease (P = 0.04) ND 
Ratio of therapeutic dose that affects cortisol or aldosterone (x clinical dose) > 10 1 > 32 
ND = no data; *samples taken at 7-day intervals; †observed in male subjects only 8 AU Buzdar 
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tamoxifen treatment. This was shown in two phase III clinical
trials of identical design which compared the effects of two
different daily doses of anastrozole (1 mg and 10 mg) with mege-
strol acetate (40 mg, four times daily) on time to progression and
overall survival. In both studies, disease had progressed after prior
tamoxifen therapy. Following initial assessment of efficacy at 6
months, anastrozole, 1 mg/day, was shown to be as effective as
megestrol acetate, but was more tolerable with regard to weight-
gain. The identical design of both trials allowed a prospectively
planned combined analysis to be performed, thus strengthening the
statistical power of the observations made in both trials, while also
providing a survival update based on mature data at a median
follow-up of 31 months, when over 60% of the patients had died.
The combined analysis demonstrated that anastrozole significantly
increased median survival compared with megestrol acetate 
(22.5 months in the megestrol acetate group vs 26.7 months in 
the anastrozole 1 mg/day group, P<0.025) (Buzdar et al, 1998).
No additional benefit was observed with anastrozole 10 mg
(median survival 25.5 months, not significant), endorsing the
choice of 1 mg as the clinical dose. Anticipated adverse events
were pre-identified on the basis of the recognized pharmacology of
both agents and were monitored in both treatment arms at 6
months. Of these anticipated events, no statistically significant
differences were observed between either treatment arm, with the
exception of weight-gain. This is a major problem associated with
megestrol acetate therapy, with a significant proportion of patients
complaining of an increase in weight (P<0.0001) (Buzdar et al,
1998). Moreover, the weight-gain experienced by patients
receiving megestrol acetate continued to increase over time. In
contrast, no significant increase in weight was reported in patients
receiving either dose of anastrozole (Figure 2). Anastrozole was
subsequently approved by the US Food and Drug Administration
for second-line use in the treatment of postmenopausal women
with advanced breast cancer. 
Anastrozole as a first-line agent in advanced disease 
A clinical programme has recently compared the efficacy and
tolerability of anastrozole and tamoxifen in women with advanced
breast cancer. This programme consisted of two large, multicentre,
double-blind, double-dummy randomized trials (Study 0030,
‘North American’ trial and Study 0027, ‘TARGET’ trial
(Tamoxifen or Arimidex™ Randomized Group Efficacy and
Tolerability) performed in Europe, Australia, New Zealand, South
America and South Africa) (Nabholtz et al, 2000; Bonneterre et al,
2000). Both studies were similarly designed to allow for subse-
quent combined analysis to increase the statistical power of the
observations made, while individually they were suitably powered
to demonstrate equivalent efficacy and tolerability of the different
agents. Patients entering the study were either newly diagnosed
with advanced breast cancer or had progressed following wing
prior treatment of early disease. A drug-free period of at least 12
months was required for those patients receiving prior adjuvant
tamoxifen therapy. Hormone receptor status of the patients was
determined, and patients were randomized to receive either
anastrozole 1 mg/day, or tamoxifen 20 mg/day. The primary end-
point that was assessed was time to progression, with objective
response, clinical benefit (complete response + partial response +
stable disease ≥24 weeks) and tolerability also measured. 
Results from the ‘North American trial’, in which the majority
(89%) of patients were known to be oestrogen- or progesterone-
receptor-positive, indicated a clear superiority of anastrozole over
tamoxifen in terms of time to disease progression (TTP = 11.1 vs
5.6 months for anastrozole and tamoxifen, respectively, P = 0.005)
and clinical benefit (59% vs 46% for anastrozole and tamoxifen,
respectively, P = 0.0098). The hazard ratio (1.44, lower one-sided
95% confidence limit = 1.16) also indicated that patients receiving
anastrozole displayed a 44% longer disease-free survival period
than those in the tamoxifen arm. 
In the larger, TARGET study (Bonneterre et al, 2000), only 45%
of the study population were known to be oestrogen- or proge-
sterone-receptor-positive. However, anastrozole was at least as
effective as tamoxifen in these patients (median TTP 8.2 vs 8.3
months for anastrozole vs tamoxifen, respectively). When data
from both studies were combined in a retrospective analysis of
those patients known to be hormone-receptor-positive, anastrozole
was again shown to be significantly superior to tamoxifen (median
TTP 10.7 vs 6.4 months for anastrozole and tamoxifen, respec-
tively, two-sided P = 0.022, Figure 3). Furthermore, a smaller
study that included individuals who had hormone-sensitive
tumours but who had not previously received hormonal therapy,
was reported recently. The data showed a significant improvement
in TTP (10.6 months in the anastrozole arm vs 5.3 months in the
tamoxifen group, P < 0.05) similar to that observed in the North
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Figure 2 Weight-gain over time. 9-month data update of anastrozole vs
megestrol acetate (reproduced with kind permission of John Wiley and Sons
Inc. from Buzdar et al, 1998) 
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American study, and a survival advantage for anastrozole
compared with tamoxifen for first-line treatment (Milla-Santos 
et al, 2000). 
In the two pivotal first-line trials, both anastrozole and tamox-
ifen were shown to be well tolerated with approximately 5% of
patients in both treatment arms being withdrawn from the study as
a result of adverse events, and 2% of these withdrawals considered
to be drug-related. However, when predefined adverse events were
considered in the combined analysis of both trials (i.e. those that
are predicted to occur due to the known pharmacology of either
agent), significantly fewer thromboembolic events (3.6% vs 6.5%,
P = 0.043, not adjusted for multiple comparisons) (AstraZeneca,
data on file) and less vaginal bleeding (1% vs 2.2%) were
observed in patients receiving anastrozole (Buzdar et al, 2000).
Moreover, data from the combined analysis indicates no clinically
significant effect on blood lipid profiles after 108 weeks’ follow-
up (Dewar et al, 2000), or any significant difference in the
frequency of bone fractures in either treatment arm (2.2% in 
the anastrozole group vs 2.9% in the tamoxifen group)
(AstraZeneca, data on file). These data are particularly reassuring
given the concern that has been raised regarding the powerful
oestrogen-suppressing effects of the third-generation aromatase
inhibitors, such as anastrozole. The North American and the
TARGET studies indicate that anastrozole is superior to tamoxifen
in postmenopausal women with advanced disease who are known
to be hormone-receptor-positive. Subsequently, anastrozole has
now received approval for first-line treatment of advanced breast
cancer in postmenopausal women in many countries. 
ANASTROZOLE IN EARLY BREAST CANCER 
The clinical experience of anastrozole in the treatment of
advanced disease, outlined above, clearly highlights that this agent
also meets the necessary criteria for evaluation as an effective
adjuvant therapy in postmenopausal women. These criteria
include superior efficacy over existing adjuvant agents, improved
tolerability and easy and convenient dosing. 
Given anastrozole’s superior efficacy compared with tamoxifen
in advanced disease, it was postulated that anastrozole would be
superior in the treatment of early disease. Tolerability assumes
greater importance in the adjuvant setting when the duration 
of therapy extends to 5 years. Anastrozole’s improved side-
effect profile compared with tamoxifen particularly in terms of
thromboembolic events and vaginal bleeding, make it an attractive
candidate for such use. 
The ATAC trial 
The ATAC trial was designed to determine whether long-term
anastrozole therapy may be an alternative or a complement to
tamoxifen in the adjuvant setting. The combination arm of the
study may determine whether oestrogen blockade by two different
mechanisms – suppression of oestrogen synthesis by aromatase
inhibition and prevention of oestrogen binding to its receptor by
tamoxifen – provides additional benefits over either agent used
alone. 
The ATAC trial is the largest single adjuvant breast cancer trial
ever to be conducted in postmenopausal women with early breast
cancer. Recruitment is now complete with over 9366 patients
included, from 380 centres in 21 countries. The trial is a random-
ized double-blind, three-arm study (Figure 4), statistically
powered to demonstrate equivalence of anastrozole and tamox-
ifen, and superiority of the combination arm over tamoxifen alone,
on the primary end-points (recurrence-free survival and tolera-
bility) (Baum, 1999). Patients were randomized to receive appro-
priate therapy for 5 years following completion of primary
surgery. Secondary end-points include time to distant recurrence,
time to death and incidence of new breast cancer primaries. 
Theoretical concerns that have been raised include the potential
detrimental effects on quality of life, bone mineral density 
and impact on the endometrium. In response, a number of sub-
protocols of the ATAC trial were established which compare the
long-term effects of all three treatments concerning these specific
parameters and will also supply important additional information
on quality of life, endometrial histology and pharmacokinetics. 
The ATAC trial is the most advanced adjuvant aromatase
inhibitor study currently underway and will be the first trial to
report on the comparative effects of an aromatase inhibitor and
tamoxifen in this setting. The large size of the study will also
provide important additional information regarding international
and regional variations among the baseline and demographic data.
There is little doubt that the power of the ATAC study will be
important in answering the key question of whether an aromatase
inhibitor is superior to tamoxifen in the adjuvant setting. 
FUTURE PROSPECTS 
In the long term, prospects may also exist for using anastrozole as
a neo-adjuvant agent. Two clinical trials are already underway to
determine whether or not anastrozole provides a benefit in such a
setting – the Immediate Preoperative Arimidex, Tamoxifen, or
Combined with Tamoxifen (IMPACT) trial and the Preoperative
Arimidex Compared with Tamoxifen (PROACT) trial. 
The new indication for tamoxifen in reducing breast cancer inci-
dence in high-risk women that has been approved in the USA
suggests that anastrozole may have a role in the preventive setting
and is likely to be an additional focus of future studies. 
CONCLUSION 
Clinical evidence is growing in support of aromatase inhibitors as
an important alternative endocrine agent in the management of
postmenopausal women with hormone-sensitive advanced breast
cancer. Consequently, they are now becoming established as treat-
ments of choice over other established endocrine therapies as both
first- and second-line agents for women with advanced breast
cancer. Anastrozole appears more selective in the clinical setting
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Regular follow-up monitoring adverse events
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Figure 4 The ATAC trial study design (*surgery + radiotherapy +
chemotherapy. Patients may start trial therapy while still receiving
radiotherapy) 10 AU Buzdar 
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with respect to adrenal steroidogenesis and lack of androgenic
side-effects. This favourable profile, together with its superiority
over tamoxifen in advanced breast cancer, make it a suitable agent
for assessment of its effectiveness in the treatment of early disease.
The results of the ATAC trial will determine if its superiority over
tamoxifen in advanced disease will also translate into the early
disease setting in postmenopausal women. 
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